Toleranzia AB (TOL.ST)
SEK 0.61
(0.33%)
SEK 0.61
(0.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 6.97 Million SEK | -84.12% |
| 2022 | 43.89 Million SEK | 31.43% |
| 2021 | 33.39 Million SEK | 95.82% |
| 2020 | 17.05 Million SEK | 52.37% |
| 2019 | 11.19 Million SEK | 12.63% |
| 2018 | 9.93 Million SEK | 25.2% |
| 2017 | 7.93 Million SEK | 2.16% |
| 2016 | 7.76 Million SEK | 44.43% |
| 2015 | 5.37 Million SEK | 151.38% |
| 2014 | 2.14 Million SEK | 46.98% |
| 2013 | 1.45 Million SEK | 31.59% |
| 2012 | 1.1 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 13.29 Million SEK | 551.18% |
| 2024 Q2 | 2.04 Million SEK | 17.97% |
| 2024 Q1 | 1.73 Million SEK | -21.25% |
| 2023 Q2 | 22.14 Million SEK | 82.72% |
| 2023 Q4 | 2.19 Million SEK | -80.17% |
| 2023 Q1 | 12.12 Million SEK | -21.46% |
| 2023 FY | 7.54 Million SEK | -82.81% |
| 2023 Q3 | 11.08 Million SEK | -49.95% |
| 2022 Q2 | 2.24 Million SEK | -77.88% |
| 2022 Q3 | 4.48 Million SEK | 99.78% |
| 2022 Q4 | 15.43 Million SEK | 244.0% |
| 2022 FY | 43.89 Million SEK | 31.43% |
| 2022 Q1 | 10.15 Million SEK | 35.17% |
| 2021 Q4 | 7.5 Million SEK | -15.07% |
| 2021 Q2 | 9.2 Million SEK | 17.36% |
| 2021 FY | 33.39 Million SEK | 95.82% |
| 2021 Q1 | 7.84 Million SEK | 44.09% |
| 2021 Q3 | 8.84 Million SEK | -3.92% |
| 2020 FY | 17.05 Million SEK | 52.37% |
| 2020 Q2 | 5.89 Million SEK | 81.36% |
| 2020 Q4 | 5.44 Million SEK | 121.26% |
| 2020 Q3 | 2.45 Million SEK | -58.3% |
| 2020 Q1 | 3.25 Million SEK | -23.2% |
| 2019 Q3 | 2.75 Million SEK | 22.07% |
| 2019 FY | 11.19 Million SEK | 12.63% |
| 2019 Q2 | 2.25 Million SEK | 13.94% |
| 2019 Q1 | 1.97 Million SEK | -29.65% |
| 2019 Q4 | 4.23 Million SEK | 53.99% |
| 2018 Q4 | 2.81 Million SEK | 39.22% |
| 2018 FY | 9.93 Million SEK | 25.2% |
| 2018 Q3 | 2.01 Million SEK | -25.89% |
| 2018 Q2 | 2.72 Million SEK | 14.33% |
| 2018 Q1 | 2.38 Million SEK | 2.4% |
| 2017 Q2 | 2.27 Million SEK | 18.78% |
| 2017 FY | 7.93 Million SEK | 2.16% |
| 2017 Q3 | 1.42 Million SEK | -37.08% |
| 2017 Q1 | 1.91 Million SEK | -25.0% |
| 2017 Q4 | 2.32 Million SEK | 62.87% |
| 2016 Q1 | 1.6 Million SEK | -49.73% |
| 2016 FY | 7.76 Million SEK | 44.43% |
| 2016 Q4 | 2.54 Million SEK | 36.44% |
| 2016 Q3 | 1.86 Million SEK | 38.2% |
| 2016 Q2 | 1.35 Million SEK | -15.75% |
| 2015 Q2 | 797.67 Thousand SEK | 40.69% |
| 2015 Q1 | 566.96 Thousand SEK | 67.32% |
| 2015 Q3 | 823.46 Thousand SEK | 3.23% |
| 2015 FY | 5.37 Million SEK | 151.38% |
| 2015 Q4 | 3.19 Million SEK | 287.61% |
| 2014 FY | 2.14 Million SEK | 46.98% |
| 2014 Q4 | 338.84 Thousand SEK | 0.0% |
| 2013 FY | 1.45 Million SEK | 31.59% |
| 2012 FY | 1.1 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | 47.377% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | 81.778% |
| BioGaia AB (publ) | 507.08 Million SEK | 98.625% |
| Enzymatica AB (publ) | 79.92 Million SEK | 91.277% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | 81.761% |
| Gabather AB (publ) | 9.47 Million SEK | 26.409% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | 53.158% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | 74.613% |
| Nanexa AB (publ) | 135.78 Million SEK | 94.865% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | 76.846% |
| ODI Pharma AB | -5.00 SEK | 139440100.0% |
| Orexo AB (publ) | 659.4 Million SEK | 98.943% |
| Probi AB (publ) | 208.93 Million SEK | 96.663% |
| Swedencare AB (publ) | 1.12 Billion SEK | 99.382% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 99.926% |
| Vivesto AB | 355.71 Million SEK | 98.04% |